Production of IL-16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions
© Skundric et al; licensee BioMed Central Ltd. 2006
Received: 07 April 2006
Accepted: 26 May 2006
Published: 26 May 2006
Multiple sclerosis (MS) is a central nervous system-specific autoimmune, demyelinating and neurodegenerative disease. Infiltration of lesions by autoaggressive, myelin-specific CD4+Th1 cells correlates with clinical manifestations of disease. The cytokine IL-16 is a CD4+ T cell-specific chemoattractant that is biased towards CD4+ Th1 cells. IL-16 precursor is constitutively expressed in lymphocytes and during CD4+ T cell activation; active caspase-3 cleaves and releases C-terminal bioactive IL-16. Previously, we used an animal model of MS to demonstrate an important role for IL-16 in regulation of autoimmune inflammation and subsequent axonal damage. This role of IL-16 in MS is largely unexplored. Here we examine the regulation of IL-16 in relation to CD4+ Th1 infiltration and inflammation-related changes of axonal cytoskeleton in MS lesions.
We measured relative levels of IL-16, active caspase-3, T-bet, Stat-1 (Tyr 701), and phosphorylated NF(M+H), in brain and spinal cord lesions from MS autopsies, using western blot analysis. We examined samples from 39 MS cases, which included acute, subacute and chronic lesions, as well as adjacent, normal-appearing white and grey matter. All samples were taken from patients with relapsing remitting clinical disease. We employed two-color immunostaining and confocal microscopy to identify phenotypes of IL-16-containing cells in frozen tissue sections from MS lesions.
We found markedly increased levels of pro- and secreted IL-16 (80 kD and 22 kD, respectively) in MS lesions compared to controls. Levels of IL-16 peaked in acute, diminished in subacute, and were elevated again in chronic active lesions. Compared to lesions, lower but still appreciable IL-6 levels were measured in normal-appearing white matter adjacent to active lesions. Levels of IL-16 corresponded to increases in active-caspase-3, T-bet and phosphorylated Stat-1. In MS lesions, we readily observed IL-16 immunoreactivity confined to infiltrating CD3+, T-bet+ and active caspase-3+ mononuclear cells.
We present evidence suggesting that IL-16 production occurs in MS lesions. We show correlations between increased levels of secreted IL-16, CD4+ Th1 cell inflammation, and phosphorylation of axonal cytoskeleton in MS lesions. Overall, the data suggest a possible role for IL-16 in regulation of inflammation and of subsequent changes in the axonal cytoskeleton in MS.
Multiple sclerosis (MS) is an inflammatory, demyelinating and neurodegenerative disease of central nervous system (CNS) [1, 2]. The complex immunopathology of MS is initiated by infiltration of macrophages and lymphocytes into brain and spinal cord . In patients with MS, magnetic resonance imaging (MRI) has confirmed that intrathecal infiltration correlates with clinically active, acute, and relapsing stages of disease. Infiltrating immune cells – comprised of myelin-specific and nonspecific autoaggressive and regulatory T cells, B cells, NK, NK-T and dendritic cells – are essential for myelin stripping, degeneration of axonal cytoskeleton, and/or damage to oligodendrocytes in MS lesions . Based on a gradually decreasing extent of inflammation over time, MS lesions are typically classified as acute, subacute and chronic . In multifaceted interactions between infiltrating cells, and between infiltrating cells and local glial cells and/or axons, a CD4+ Th1 cell subset has an exceptional role because it includes potentially autoaggressive cells specific for immunodominant epitopes of myelin proteins. Regulation of Th1 immunity, which includes differentiation of naïve CD4+ T cells into IFNγ-producing Th1 cells, is tightly controlled by T-bet, a member of T-box transcription factor family. In Th1-mediated autoimmune diseases, T-bet is instrumental for generation of autoreactive CD4+ Th1 cells [6–8]. Induction of T-bet depends on signaling through the signal transducer and activator of transcription-1 (Stat-1). Activation of Stat-1 occurs through phosphorylation of either tyrosine-701 or serine-727 [9, 10].
Homing of mononuclear cells, including encephalitogenic CD4+ Th1 cells, into the CNS is tightly regulated by chemoattractant factors . As opposed to chemokines, which bind to chemokine-specific receptors and do not discriminate between distinct cell phenotypes, IL-16 binds to CD4 co-receptors and selectively chemoattracts CD4+ T cells [12–14]. More importantly, the chemotactic properties of this cytokine are biased towards a Th1 subset, because of the close functional relationship between CD4 molecules and CCR5 . The human IL-16 precursor (pro-IL-16) is a 631-amino acid, two-PDZ domain-containing protein that is constitutively produced in unstimulated peripheral T lymphocytes. Following CD4+ T cell activation through T cell receptors (TCR) or by cytokines, active caspase-3 cleaves a 121-amino acid C-terminal portion, which is then secreted and becomes available to bind to CD4 receptors. In addition to CD4+ T cell migratory responses, IL-16 also regulates T cell activation, growth, CD25 and MHC class II expression, cytokine synthesis, and modulation of chemokine-induced chemoattraction [16, 17]. Thus, IL-16 is a proinflammatory and immunoregulatory cytokine, which has an important role in recruitment and activation of CD4+ Th1 cells .
We previously reported a prominent role for IL-16 in immune regulation of relapsing-remitting EAE in mice, which impacted the severity of relapsing disease, of inflammation, and of demyelination, as well as the extent of axonal damage . We provided evidence of regulation of IL-16 in EAE, which suggested that production of secreted IL-16 occurs within the CNS, and that IL-16 has a role in specific chemoattraction of CD4+ T cells in EAE . However, the regulation of IL-16 in MS itself, and the potential significance of IL-16 in regulating specific CD4+ Th1 inflammation and subsequent tissue damage in MS remain largely unexplored.
In this study we investigated correlations between the regulation of IL-16, regulation of CD4+Th1 inflammation, and inflammation-induced changes in axonal cytoskeleton in lesions sampled from 39 autopsies of patients with MS and 19 controls. We found marked increases in IL-16 and active caspase-3 expression in lesions and in adjacent normal appearing white matter (NAWM). Similarly, specific increases in T-bet and phosphorylated Stat-1 were measured in MS lesions, providing a correlation between CD4+ Th1 inflammation and intrathecal IL-16 production. We observed T-bet+IL-16+ infiltrating cells in MS lesions. Increases in phosphorylated neurofilament medium and heavy chains [NF (M+H) P] suggested initial, inflammation-induced changes in axonal cytoskeleton in MS lesions and NAWM. We observed IL-16 adjacent to abnormal-appearing axonal cytoskeletons. Overall, our data suggest a role for IL-16 in immune regulation of CD4+ Th1-specific inflammation, and subsequent changes in axonal cytoskeleton, in MS.
Summary of clinical data
Number of cases
Age (years – mean ± SD, range)
59 ± 15 (34–78)
54 ± 13 (31 – 66)
24 ± 9
21 ± 6
Duration of MS (years)
22 ± 11
A total of 62 frozen blocks (0.5–1 cm3) of brain and spinal cord tissue were dissected. These included 13 acute (AL), 13 sub-acute (SAL), and 13 chronic (CL) MS lesions, 17 adjacent areas of macroscopically normal-appearing white (NAWM), and 6 areas of normal-appearing grey matter (NAGM). From each tissue block, 10-μm frozen sections were cut or tissue was homogenized for protein isolation.
Proteins were isolated from snap-frozen tissue blocks of approximately 1 g wet weight. Tissue was homogenized in Tris-HCl buffer (100 mM Tris, pH 8.1 with 1% Triton X-100)  by sonication. Tissue suspensions were spun at 20,000 g for 45 minutes at 4°C. Supernatants were collected and stored at -70°C until use. Protein concentrations were determined by the Lowry method. Equal amounts of protein (approximately 30 μg/lane) from each sample were loaded per lane for western blot analysis. Protein samples were loaded with reducing conditions, and resolved by electrophoresis in NuPage Bis-Tris (4–12%) gels (Invitrogen, Carrsbad, CA). Electrophoresed proteins were then transferred from the gel onto nitrocellulose membrane. The membrane was blocked, and then probed with the appropriate primary antibody overnight at 4°C, washed three times with 0.1% Tween 20- Tris-buffered saline, and than incubated with peroxidase-conjugated secondary antibody. The membrane-bound peroxidase activity was detected by using ECL Plus western blotting detection kits (Amersham, Arlington Heights, IL). Chemiluminescent images were captured and analyzed by a Kodak Digital Science Image Station 440 CF. All blots were studied within the linear range of exposure. In each sample, levels of IL-16, active caspase-3, T-bet, Stat-1 (Tyr701), and NF (M+H)-P, were normalized to corresponding levels of GAPDH.
Immunostaining and confocal microscopy
Primary antibodies used for immunostaining and western blot
BD Biosciences San Diego CA
BD Biosciences San Diego CA
BD Biosciences San Diego CA
R&D Systems Minneapolis MN
R&D Systems Minneapolis MN
Biolegend San Diego CA
Cell Signaling Technology Co Danvers MA
Cell Signaling Technology Co Danvers MA
Chemicon Temecula CA
Santa Cruz Biotechnology Santa Cruz CA
BD Biosciences San Diego CA
BD Biosciences San Diego CA
Caltag Laboratories Bulingame CA
BD Biosciences San Diego CA
Caltag Laboratories Bulingame CA
Caltag Laboratories Bulingame CA
All statistical analyses were done using GraphPad Prism software (GraphPad, San Diego, CA). The significance of differences between groups was calculated using Student's t-test. The level of statistical significance was set at p < 0.05.
Levels of pro- and secreted IL-16 are distinctly regulated in acute, subacute and chronic MS lesions in brain and spinal cord
Mature IL-16 showed patterns similar to those of pro-IL-16. Mature IL-16 was also undetectable in control brain white matter by western blot. An abundant presence of secreted IL-16 was measured in acute, subacute and especially in chronic MS lesions in brain. Differences between these types of lesions were not significant. NAWM and NAGM showed secreted levels of IL-16 that were approximately one half to one fifth those of acute MS lesions, but still appreciable by western blot, especially in NAWM (Fig. 1A). In normal spinal cord, secreted IL-16 was detected at very low levels. In acute spinal cord lesions, the content of secreted IL-16 was over ten times higher than basal levels. Significant downregulation of secreted IL-16 was observed in subacute and chronic lesions and in NAWM, in comparison to acute lesions (Fig. 1B). The relative levels of IL-16 in spinal cord appear to be consistently higher than those of brain.
Regulation of active caspase-3 parallels secreted IL-16 and suggests a role for this caspase in enzymatic cleavage of pro-IL-16 in MS lesions
Within MS lesions, elevated levels of secreted IL-16 correspond to increased CD4+ Th1 infiltration and signaling, as measured by T-bet expression, and Stat-1 phosphorylation
Intrathecal levels of Stat-1 (Tyr 701) were undetectable in controls, but were found at appreciable levels in acute MS lesions, and at lower levels in subacute and chronic MS lesions in brain and spinal cord (Fig. 3C). Regulation of Stat-1 (Tyr 701) correlated well with trends measured for T-bet and secreted IL-16 in MS lesions. In contrast to increased phosphorylation of Stat-1, we did not detect phosphorylated Stat-6 (Tyr641) (not shown), suggesting that Stat-1-specific signaling is preferential over Stat-6-specific activation in MS lesions.
Extensive IL-16 immunostaining, confined to infiltrating cells, was observed in MS lesions. Less widespread immunostaining was found in normal-appearing white matter of brain and spinal cord. IL-16 immunoreactivity was readily observed in CD3+ T cells in perivenular infiltrates (Fig. 6A). Within the pool of infiltrating mononuclear cells, a subset of T-bet+ cells frequently expressed IL-16 (Fig. 4A). IL-16 nuclear immunostaining was seldom observed, while IL-16 often appeared as cytoplasmic or membrane-bound immunostaining, or adjacent to cells as secreted product. IL-16 was found frequently between adjoining mononuclear cells (Fig. 4A and 4B).
In addition to co-localization with CD3+ and CD4+ T cells, some IL-16 immunoreactivity was confined to CD8+ T cells, CD20+ B cells, and CD83+ dendritic cells (not shown). Occasional Mac-1+ microglia were IL-16+, while the majority of cells expressing Mac-1 did not contain IL-16 (not shown).
Intrathecal production of IL-16 correlates with increased levels and fragmentation of phosphorylated neurofilament medium and heavy chains [NF(M+H)]P
Phosphorylated neurofilament medium (160 kD) and heavy (220 kD) chains [NF(M+H)]P, were detected in control brain and spinal cord tissue at appreciable levels.
Abnormalities in appearance of phosphorylated neurofilaments (medium and heavy) chains [NF(M+H)]P, were observed in MS lesions and, interestingly, also in NAWM. Small, rounded, irregularly shaped fragments of neurofilaments were readily observed (Fig. 6B). IL-16 immunostaining was found either confined to mononuclear cells or in the proximity of cells adjacent to irregular appearing neurofilaments (Fig. 6B).
Our observations suggest an important role for the cytokine IL-16 in regulation of CD4+ T cell infiltration, of severity and frequency of relapses, and of subsequent demyelination and axonal damage, in a mouse model of EAE . These observations suggest that IL-16, which serves as a specific ligand for the CD4 co-receptor, may have a similar role or roles in regulation of MS. In other organs, increased levels and processing of IL-16 is associated with the pathogenesis of delayed type hypersensitivity  and autoimmunity, such as in atopic dermatitis , with autoimmune rheumatoid arthritis and lupus [25, 26]. However, the role of IL-16 regulation in MS lesions is largely unknown. With the exception of one report, which shows IL-16 immunoreactivity within lesions of a single case of MS, this has been little studied and the mechanisms of IL-16 regulation in MS remain elusive . In this previous study, it was not apparent if IL-16 expression in MS differed from that of control adult CNS, or if the IL-16 expression was due to precursor or secreted IL-16. The cellular localization of IL-16 immunoreactivity suggested expression in microglia-like cells, although it did not correspond with the expression of several microglia activation markers. Some of the IL-16 immunoreactivity was found to be related to lymphocytes and astrocyte-like cells.
To asses the potential role of locally produced IL-16 in regulation of neuroinflammation and axonal damage, key markers of MS pathology, we specifically addressed the following questions: Does production of mature IL-16 occur within MS lesions? What are the phenotypes of IL-16-containing or -producing cells? Does intrathecal IL-16 accumulation correlate with specific CD4+ Th1 inflammation and damage of axonal cytoskeletons?
Here we present our findings on the expression and distinct regulation of pro- and secreted IL-16 in acute, subacute and chronic MS lesions, and in normal-appearing white matter, from brain and spinal cord of 39 patients with MS and 19 normal controls.
As anticipated, the highest levels of pro- and secreted IL-16 were found in acute lesions. The marked increases in secreted IL-16 over control levels in brain and spinal cord suggests a role for IL-16 in regulation of neuroinflammation in acute lesions. Locally produced IL-16 may further support production of inflammatory cytokines by infiltrating mononuclear cells, in a fashion similar to that seen in vitro . In this way, IL-16 may support inflammation in a complex network of pro- and anti- inflammatory pathways occurring in acute lesions [28, 29]. Surprisingly high levels of secreted IL-16 in chronic lesions, and lower but still above normal levels in normal appearing white matter, may be due to generalization of inflammatory and degenerative processes beyond focal demyelinating plaques and beyond macroscopically defined lesions. Such pathology is consistent with diffuse inflammation and with accumulating axonal injury during the progressive course of MS, as suggested by others . Alternatively, IL-16 found in chronic lesions and in normal white and grey matter adjacent to lesions may originate from neuronal IL-16 (NIL-16). Lymphoid IL-16 is transcribed from an intronic promoter lying within the NIL-16 gene. C-terminal regions of IL-16 and NIL-16 share 100% similarity. NIL-16 is produced by neurons primarily in cerebellum and in hippocampus. In vitro, at least, neuronal apoptosis leads to cleavage of NIL-16 by active caspase-3 and secretion of C-terminal bioactive IL-16 . Whether similar mechanisms operate in vivo during neuronal damage is not known. The lack of NIL-16 in normal control samples may reflect the anatomic distribution of NIL-16 expression. Alternatively, epitope for mAb 14.1 may be masked in NIL-16. Even if this antibody does detect intact NIL-16, following cleavage with active caspase-3, it would not detect the N-terminal domain of NIL-16. Our finding of IL-16 in MS tissue devoid of macroscopically significant mononuclear infiltration and/or microglial activation argues for a role for IL-16 in progression and spreading of focal inflammatory lesions. Our data showing substantially increased secreted IL-16 in CNS of mice with chronic EAE  support this proposed role for IL-16.
Slight differences were observed between brain and spinal cord in regulation of IL-16, active caspase-3, T-bet, Stat-2 (Tyr701) and NF(M+H)P, which may suggest the existence of distinct regulatory mechanisms of neuroinflammation in these two regions. The absence of appreciable IL-16 expression in control brain and spinal cord argues against an important physiological role for IL-16 in the maintenance of homeostasis within normal CNS.
In MS lesions, putative producers of IL-16 include CD4+, CD8+ T cells, B cells, dendritic cells, and subsets of activated microglia. Locally produced bioactive IL-16 may exert its paracrine effects by binding to CD4 co-receptor. A minimal peptide RRKS, between Arg106 and Ser109 of C-terminally cleaved bioactive IL-16, is essential for the binding and signaling through CD4 . This specific localization of intrathecal IL-16 bears relevance to its several potentially important roles: in local immunomodulation through regulation of CD4+T-T cell communication; in CD4+T cell helper function in the processes of T-B cell communication; and lastly in local antigen presentation by dendritic cells and microglia. A role for IL-16 in the cross talk between dendritic cells and T cells has also been proposed .
The Stat-1 protein plays a central role in the biological activity of both type I and type II interferons. Th1-derived IFNγ binds to its specific receptor on the surface of T cells and initiates signaling cascade, which includes Stat-1 phosphorylation and nuclear translocation. T-bet is regulated by IFNγ-, Stat-1-mediated signaling, and its level is markedly reduced in IFNγ- or Stat-1-mutant cells .
Inflammation-induced changes in axonal cytoskeletons, which include increased levels of phosphorylated medium and heavy chains of neurofilament, readily lead to axonal dysfunction [1, 35]. Our finding of IL-16 immunoreactivity in the vicinity of degenerate neurofilaments, which appears to be secreted from mononuclear cells (Fig. 6), suggests that this proinflammatory cytokine may participate in damage to axonal cytoskeletons.
We find extensive production of IL-16 in MS lesions and in adjacent normal-appearing white (NAWM) and grey matter (NAGM) in both brain and spinal cord of MS patients. Increased levels of secreted IL-16 correlated with elevated levels of active caspase-3, T-bet and Stat-1 (Tyr701). Within both MS lesions and NAWM, active-caspase-3+ IL-16+, and T-bet+IL-16+ mononuclear cells were readily observed. A specific localization of IL-16 to sites of cell-cell contact was frequently observed, suggesting a role in cell-to-cell communication. We found similarities in patterns of regulation between secreted IL-16 and active caspase-3 that suggest production of secreted IL-16 within lesions by active caspase-3-dependent cleavage of pro-IL-16. Conversely, similarities in patterns of regulation between IL-16, T-bet and Stat-1 (Tyr701) suggest contributions of CD4+Th1 cell subsets to IL-16 local production, and/or a role for locally produced secreted IL-16 in CD4+Th1 cell homing.
Increased production of secreted IL-16 corresponded with marked elevations in phosphorylated neurofilament medium and heavy chains, suggesting inflammation-induced changes in axonal cytoskeleton in MS lesions and NAWM. IL-16+ mononuclear cells were observed adjacent to these axons; these were frequent in MS lesions and sparse in NAWM.
Taken together, our data suggest an important role for intrathecally secreted IL-16 in specific regulation of CD4+Th1 cell homing, Th1-mediated neuroinflammation, and subsequent changes in axonal cytoskeleton in MS. Our results also suggest a role for IL-16 in processes of cell-to-cell communication in MS lesions.
experimental autoimmune encephalomyelitis
normal appearing white matter
normal appearing grey matter
normal control white matter
normal control grey matter
phosphorylated medium and heavy chains of neurofilament
signal transducer and activator of transcription-1
We thank the Chairman, Dr Robert P. Lisak for the support from Parker Webber Funds, and Dr Joyce Benjamins for critical reading of the manuscript. D.G. was supported by Multiple Sclerosis Society of Great Britain. We thank Ms Jessica De Jullian for technical assistance in manuscript preparation.
- Bjartmar C, Trapp BD: Axonal degeneration and progressive neurology disability in multiple sclerosis. Neurotox Res. 2003, 5: 157-64.View ArticlePubMedGoogle Scholar
- Lassmann H, Bruck W, Lucchinetti C: Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med. 2001, 7: 11-21. 10.1016/S1471-4914(00)01909-2.View ArticleGoogle Scholar
- Hickey WF, Hsu BL, Kimura H: T-lymphocyte entry into the central nervous system. J Neurosci Res. 1991, 28: 254-60. 10.1002/jnr.490280213.View ArticlePubMedGoogle Scholar
- Steinman L: Immune therapy for autoimmune diseases. Science. 2004, 305: 212-216. 10.1126/science.1099896.View ArticlePubMedGoogle Scholar
- Li H, Newcombe J, Croome NP, Cuzner MI: Characterization and distribution of phagocytic macrophages in multiple sclerosis plaques. Neuropath Appl Neurobiol. 1993, 19: 214-23.View ArticleGoogle Scholar
- Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH: A Novel Transcription Factor, T-bet, Directs TH1 Lineage Commitment. Cell. 2000, 100: 655-69. 10.1016/S0092-8674(00)80702-3.View ArticlePubMedGoogle Scholar
- Lovett-Racke AE, Rocchini AE, Choy J, Northrop SC, Hussain RZ, Ratts RB, Sikder D, Racke NK: Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. Immunity. 2004, 21: 719-31. 10.1016/j.immuni.2004.09.010.View ArticlePubMedGoogle Scholar
- Robinson DS, O'Garra A: Further checkpoints in Th1 development. Immunity. 2002, 16: 755-58. 10.1016/S1074-7613(02)00331-X.View ArticlePubMedGoogle Scholar
- Imada K, Leonard WJ: The Jak-STAT pathway. Mol Immunol. 2000, 37: 1-11. 10.1016/S0161-5890(00)00018-3.View ArticlePubMedGoogle Scholar
- Lee YJ, Benveniste EN: Start1 alpha expression is involved in IFN-gamma induction of the class II transactivator and class II MHC genes. J Immunol. 1996, 157: 1559-68.PubMedGoogle Scholar
- Trebst C, Ransohoff RM: Investigating chemokines and chemokine receptors in patients with multiple sclerosis. Arch Neurol. 2001, 58: 1975-80. 10.1001/archneur.58.12.1975.View ArticlePubMedGoogle Scholar
- Cruikshank W, Center DM: Modulation of lymphocyte migration by human lymphokines. II. Purification of lymphotactic factor (LCF). J Immunol. 1982, 128: 2569-71.PubMedGoogle Scholar
- Cruikshank W, Kornfeld H, Center DM: Interleukin-16. J Leukocyte Biol. 2000, 67: 757-66.PubMedGoogle Scholar
- Wilson KC, Center DM, Cruikshank WW: The Effect of Interleukin-16 and its Precursor on T Lymphocyte Activation and Growth. Growth Factors. 2004, 22: 97-104. 10.1080/08977190410001704679.View ArticlePubMedGoogle Scholar
- Lynch EA, Heijens CA, Horst NF, Center DM, Cruikshank WW: Cutting edge: IL 16/CD4 preferentially induces Th1 cell migration: requirement of CCR5. J Immunol. 2003, 171: 4965-68.View ArticlePubMedGoogle Scholar
- Cruikshank WW, Center DM, Nisar N, Wu M, Natke B, Theodore AC, Kornfeld H: Molecular and functional analysis of a lymphocyte chemoattractant factor: Association of biologic function with CD4 expression. Proc Natl Acad Sci USA. 1994, 91: 5109-13.PubMed CentralView ArticlePubMedGoogle Scholar
- Mathy NL, Scheuer W, Lanzendorfer M, Honold K, Ambrosius D, Norley S, Kurth R: Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunol. 2000, 100: 63-69. 10.1046/j.1365-2567.2000.00997.x.View ArticleGoogle Scholar
- Center DM, Kornfeld H, Cruikshank WW: Interleukin 16 and its function as a CD4 ligand. Immunol. 1996, 17: 476-81.Google Scholar
- Skundric DS, Dai R, Zakarian VL, Bessert D, Skoff RP, Cruikshank WW, Kurjakovic Z: Anti-IL-16 Therapy Reduces CD4+ T-Cell Infiltration and Improves Paralysis and Histopathology of Relapsing EAE. J Neurosci Res. 2005, 79: 680-93. 10.1002/jnr.20377.View ArticlePubMedGoogle Scholar
- Skundric DS, Zhou W, Cruikshank WW, Dai R: Increased level of bioactive IL-16 correlate with disease activity during relapsing experimental autoimmune encephalomyelitis (EAE). J Autoimmun. 2005, 25: 206-14. 10.1016/j.jaut.2005.09.016.View ArticlePubMedGoogle Scholar
- Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983, 33: 1444-52.View ArticlePubMedGoogle Scholar
- Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, Newcombe J: The expression of tissue type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis-comparison of stages in lesion evolution. J Neuropath Exp Neurol. 1996, 55: 1194-204.View ArticlePubMedGoogle Scholar
- Yoshimoto T, Wang CR, Yoneto T, Matsuzawa A, Cruikshank WW, Nariuchi H: Role of IL-16 in delayed-type hypersensitivity reaction. Blood. 2000, 95: 2869-74.PubMedGoogle Scholar
- Laberge S, Ghaffar O, Boguniewicz M, Center DM, Leung DY, Hamid Q: Association of increased CD4+ T-Cell infiltration with increased IL-16 gene expression in atopic dermatitis. J Allergy Clin Immunol. 1998, 102: 645-74. 10.1016/S0091-6749(98)70282-9.View ArticlePubMedGoogle Scholar
- Franz JK, Kolb SA, Hummel KM, Lahrtz F, Neidhart M, Aicher WK, Pap T, Gay RE, Fontana A, Gay S: Interleukin-16, produced by synovial fibroblasts, mediates chemoattraction for CD4+T lymphocytes in rheumatoid arthritis. Eur J Immunol. 1998, 28: 2661-71. 10.1002/(SICI)1521-4141(199809)28:09<2661::AID-IMMU2661>3.0.CO;2-N.View ArticlePubMedGoogle Scholar
- Lard LR, Roep BO, Verburgh CA, Zwinderman AH, Huizinga TW: Elevated Il-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus. Lupus. 2002, 11: 181-5. 10.1191/0961203302lu176sr.View ArticlePubMedGoogle Scholar
- Schluesener HJ, Seid K, Kretzschmar J, Meyermann R: Leukocyte Chemotactic Factor, a Natural Ligand to CD4, is Expressed by Lymphocytes and Microglial Cells of the MS-Plaque. Neurosci Res. 1996, 44: 606-611. 10.1002/(SICI)1097-4547(19960615)44:6<606::AID-JNR11>3.0.CO;2-W.View ArticleGoogle Scholar
- Gveric D, Cuzner ML, Newcombe J: Insulin-like growth factors and binding proteins in multiple sclerosis plaques. Neuropath and App Neurobio. 1999, 25: 215-25. 10.1046/j.1365-2990.1999.00187.x.View ArticleGoogle Scholar
- Gveric D, Herrera BM, Cuzner ML: Receptors and the Fibrinolytic Response in Multiple Sclerosis Lesions. Am J Pathol. 2005, 166: 1143-51.PubMed CentralView ArticlePubMedGoogle Scholar
- Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H: Corticol demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005, 128: 2705-12. 10.1093/brain/awh641.View ArticlePubMedGoogle Scholar
- Kurschner C, Yuzaki M: Neuronal Interleukin-16 (NIL-16): A Dual Function PDZ Domain Protein. Neurosci. 1999, 19: 7770-7780.Google Scholar
- Nicoll J, Cruikshank WW, Brazer W, Lui Y, Center DM, Kornfeld H: Identification of Domain in IL-16 Critical for Biological Activity. Immunol. 1999, 163: 1827-1832.Google Scholar
- Kaser A, Dunzendorfer S, Offner FA, Ryan T, Schwabegger A, Cruikshank WW, Wiedermann CJ, Tilg H: A role for IL-16 in the cross-talk between dendritic cells and T cells. J Immunol. 1999, 163: 3232-8.PubMedGoogle Scholar
- Lighvani AA, Frucht DM, Jankovic D, Yamane H, Aliberti J, Hissong BD, Nguyen BV, Gadina M, Sher A, Paul WE, O'Shea JJ: T-bet is rapidly induced by interferon-γ in lymphoid and myeloid cells. PNAS. 2001, 98: 1537-42. 10.1073/pnas.261570598.View ArticleGoogle Scholar
- Petzold A: Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss. Neuro Sci. 2005, 233: 9183-198.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.